Valiant Organics H1-FY27 PAT tops FY26 as margin hits 15%
Key highlights
- Valiant Organics reported consolidated H1-FY27 PAT of Rs 46.6 crore, above FY26 PAT of Rs 33.2 crore.
- Valiant Organics’ consolidated H1-FY27 EBITDA margin was 15.04%, compared with 11.94% in FY26.
- Valiant Organics’ consolidated H1-FY27 revenue was Rs 535.8 crore and EBITDA was Rs 80.6 crore.
- Valiant Organics’ standalone Q2-FY27 EBITDA margin was 12.82%, below Q1-FY27’s 17.97%.
powered by IRIS

Valiant Organics Limited reported consolidated profit after tax (PAT) of Rs 46.6 crore in H1-FY27, exceeding the Rs 33.2 crore reported for all of FY26, while earnings before interest, tax, depreciation and amortisation (EBITDA) margin reached 15.04% from 11.94% in FY26. The half-year profit followed consolidated losses in FY24 and FY25.
Know Valiant Organics inside out
Results, valuation, peers and who's buying, in one view.
How did Valiant Organics’ H1-FY27 profit compare with FY26?
Valiant Organics’ consolidated PAT was Rs 46.6 crore in H1-FY27, Rs 13.4 crore above FY26 PAT of Rs 33.2 crore despite H1-FY27 covering only six months. PAT margin was 8.70% in H1-FY27, compared with 4.49% in FY26, an increase of 421 basis points, where one basis point is one-hundredth of a percentage point.
The result extends a recovery across four reported periods. Valiant Organics recorded consolidated losses of Rs 8.4 crore in FY24 and Rs 3.4 crore in FY25, before reporting FY26 PAT of Rs 33.2 crore and H1-FY27 PAT of Rs 46.6 crore. Basic and diluted earnings per share were Rs 16.22 in H1-FY27, versus Rs 11.86 in FY26 and negative Rs 3.00 in FY24.
What changed in Valiant Organics’ profitability in H1-FY27?
Valiant Organics’ consolidated EBITDA increased to Rs 80.6 crore in H1-FY27 from Rs 45.9 crore in H1-FY26, while revenue from operations rose to Rs 535.8 crore from Rs 361.6 crore. That 75.8% increase in EBITDA exceeded the 48.2% rise in revenue, producing an EBITDA margin of 15.04%, compared with 12.69% in H1-FY26.
The historical series shows EBITDA margin rising from 5.28% in FY24 to 7.47% in FY25, 11.94% in FY26 and 15.04% in H1-FY27. Revenue was broadly unchanged between FY24 at Rs 723.1 crore and FY25 at Rs 718.8 crore, then increased to Rs 738.8 crore in FY26; H1-FY27 revenue of Rs 535.8 crore was equivalent to 72.5% of FY26 revenue.
Below EBITDA, consolidated depreciation was Rs 20.5 crore and finance cost was Rs 10.3 crore in H1-FY27. Profit before tax (PBT) was Rs 61.6 crore, including Rs 7.4 crore as share of profit from associates; FY26 PBT was Rs 41.9 crore and included a Rs 5.7 crore exceptional item and a Rs 1.1 crore share of loss from associates.
Did Valiant Organics’ Q2-FY27 margins hold up from Q1?
Valiant Organics’ standalone Q2-FY27 EBITDA margin was 12.82%, below 17.97% in Q1-FY27 and 13.49% in Q2-FY26. Q2 standalone EBITDA was Rs 39.0 crore, up 84.0% year on year from Rs 21.2 crore but down 6.3% sequentially from Rs 41.6 crore in Q1-FY27.
Standalone revenue rose to Rs 304.2 crore in Q2-FY27 from Rs 157.2 crore in Q2-FY26 and Rs 231.5 crore in Q1-FY27. However, total expenses increased to Rs 265.2 crore in Q2-FY27 from Rs 189.9 crore in Q1-FY27, while revenue increased by Rs 72.7 crore over the same sequential comparison.
Standalone Q2-FY27 PAT was Rs 17.2 crore, compared with Rs 5.6 crore in Q2-FY26 and Rs 21.8 crore in Q1-FY27. PAT margin was 5.65%, up from 3.56% a year earlier but down from 9.42% in Q1-FY27; the H1-FY27 standalone EBITDA margin was 15.06%.
Got a follow-up? Ask IRIS
Why was Valiant Organics’ consolidated H1-FY27 PAT above standalone PAT?
Valiant Organics reported standalone H1-FY27 PAT of Rs 39.0 crore, compared with consolidated PAT of Rs 46.6 crore. The consolidated statement includes Rs 7.4 crore as share of profit from associates, whereas the standalone statement does not carry that line; neither statement reported an exceptional item in H1-FY27.
Revenue was Rs 535.8 crore in both the standalone and consolidated H1-FY27 statements, while EBITDA was Rs 80.7 crore on a standalone basis and Rs 80.6 crore on a consolidated basis. Other income was Rs 3.7 crore standalone and Rs 4.4 crore consolidated, while tax was Rs 14.6 crore and Rs 15.0 crore, respectively.
What changed in Valiant Organics’ balance sheet by H1-FY27?
Valiant Organics’ consolidated equity increased to Rs 806.3 crore at H1-FY27 from Rs 759.4 crore at FY26, while total assets rose to Rs 1,335.2 crore from Rs 1,230.8 crore. Other equity increased to Rs 778.1 crore from Rs 731.4 crore, alongside total comprehensive income of Rs 46.6 crore for H1-FY27.
Trade receivables rose to Rs 320.3 crore at H1-FY27 from Rs 243.3 crore at FY26, and inventories increased to Rs 111.0 crore from Rs 91.5 crore. Current borrowings declined to Rs 192.1 crore from Rs 200.1 crore, while non-current borrowings increased to Rs 64.4 crore from Rs 52.6 crore.
Cash and cash equivalents were Rs 6.5 crore at H1-FY27, compared with Rs 1.8 crore at FY26. Capital work in progress increased to Rs 40.6 crore from Rs 21.2 crore, while property, plant and equipment declined to Rs 663.8 crore from Rs 679.1 crore.
Conclusion
Valiant Organics’ H1-FY27 consolidated PAT of Rs 46.6 crore exceeded its FY26 PAT of Rs 33.2 crore, supported by revenue of Rs 535.8 crore and a 15.04% EBITDA margin. The reported progression spans consolidated losses in FY24 and FY25, a return to profit in FY26, and a higher profit in the first half of FY27.
The disclosed issue to watch is whether the lower standalone Q2-FY27 EBITDA margin of 12.82%, versus 17.97% in Q1-FY27, persists in subsequent results. The presentation also leaves H1-FY27 receivables of Rs 320.3 crore, inventories of Rs 111.0 crore and capital work in progress of Rs 40.6 crore as balance-sheet items for future disclosures to clarify.


